Bora Pharmaceuticals reported consolidated revenue of NT$2.089 billion in October, marking a historic high for the seventh consecutive month, with a year-on-year increase of 85.94%. Cumulative revenue for the first ten months of the year reached NT$15.589 billion, surpassing last year's full-year total and setting a new annual record with a 28.64% growth rate.

Bora’s revenue growth in October was driven by its subsidiary Upsher-Smith Laboratories (USL), with the strongest performance coming from VIGADRONE (vigabatrin) oral suspension, a treatment for infantile spasms that has shown steady growth in both revenue and profitability.

At the end of October, Bora acquired all shares of Pyros Pharmaceuticals, a New Jersey-based rare disease drug development company, for $27.25 million (approximately NT$874 million). Expected to close in Q4, this acquisition reflects Bora’s strategic shift from a focus on generics to include branded drugs with patent protection.

Through its subsidiary USL, Bora has successfully entered the U.S. branded generic market, capitalizing on the pediatric neurology drug VIGADRONE (vigabatrin) oral suspension and USL’s specialized distribution channels.

Following the acquisition of Pyros, Bora also added a “ready-to-use” oral solution form of vigabatrin to its portfolio. This expansion strategically shifts Bora’s market from highly competitive generic drugs to the more profitable and high-growth potential of 505(b)(2) new drug formulations. With USL’s existing oral suspension and oral powder solutions, Bora is now the only pharmaceutical company in the U.S. offering all three vigabatrin formulations.

Resource (mandarin): 併購效益 保瑞10月營收連7月創新高